These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 12634730)
1. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Valcárcel D; Martino R; Caballero D; Mateos MV; Pérez-Simón JA; Canals C; Fernández F; Bargay J; Muñiz-Díaz E; Gonzalez M; San Miguel JF; Sierra J Bone Marrow Transplant; 2003 Mar; 31(5):387-92. PubMed ID: 12634730 [TBL] [Abstract][Full Text] [Related]
2. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
4. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
6. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651 [TBL] [Abstract][Full Text] [Related]
7. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300 [TBL] [Abstract][Full Text] [Related]
8. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466 [TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
10. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis. Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220 [TBL] [Abstract][Full Text] [Related]
11. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Antin JH; Childs R; Filipovich AH; Giralt S; Mackinnon S; Spitzer T; Weisdorf D Biol Blood Marrow Transplant; 2001; 7(9):473-85. PubMed ID: 11669214 [TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
13. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766 [TBL] [Abstract][Full Text] [Related]
14. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869 [TBL] [Abstract][Full Text] [Related]
15. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation]. Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044 [TBL] [Abstract][Full Text] [Related]
16. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689 [TBL] [Abstract][Full Text] [Related]
17. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088 [TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513 [TBL] [Abstract][Full Text] [Related]
19. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Chan GW; Gorgun G; Miller KB; Foss FM Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467 [TBL] [Abstract][Full Text] [Related]
20. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]